Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;5(2):E21.
doi: 10.1208/ps050221.

Atenolol quantification in human plasma by high-performance liquid chromatography: application to bioequivalence study

Affiliations

Atenolol quantification in human plasma by high-performance liquid chromatography: application to bioequivalence study

Luis Renato Pires de Abreu et al. AAPS PharmSci. 2003.

Abstract

An accurate, precise, and sensitive high-performance liquid chromatography (HPLC) assay was developed for the determination of atenolol in human plasma samples to compare the bioavailability of 2 atenolol tablet (50 mg) formulations in 24 volunteers of both sexes. The study had an open, randomized, 2-period crossover design with a 1-week washout period. Plasma samples were obtained over a 24-hour interval. Atenolol concentrations were analyzed by combined reversed phase liquid chromatography and fluorescence detection (lambda(EX) = 258 nm, lambda(EM) = 300 nm). From the atenolol plasma concentration versus time curves, the following pharmacokinetic parameters were obtained: AUC(0-24h), AUC(0- infinity ), and C(max). The geometric mean of test/reference 50-mg tablets individual percent ratio was 102.2% for AUC(0-24h), and 101.6% for C(max). The 90% confidence intervals (CI) were 100.2% to 105.4% and 100.9% to 103.5%, respectively. Since the 90% CI for both C(max) and AUC(0-24h) were within the 80% to 125% interval proposed by the Food and Drug Administration, it was concluded that atenolol (50-mg tablets) test formulation was bioequivalent to the reference formulation, with regard to both the rate and extent of absorption.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clementi WA, Garvey TQ, Clifton GD, McCoy RA, Brandt S, Schwartz S. Single dose pharmacokinetics of (S)-atenolol administered orally as a single enantiomer formulation and as a racemic mixture (Tenormin) Chirality. 1994;6(3):169–174. doi: 10.1002/chir.530060303. - DOI - PubMed
    1. Egginger G, Lindner W, Karh S, Stoschitzky K. Stereoselective HPLC bioanalysis of atenolol enantiomers in plasma: application to a comparative human pharmacokinetic study. Chirality. 1993;5:506–512. doi: 10.1002/chir.530050706. - DOI - PubMed
    1. Physicians Desk Reference-PDR, 51st ed, Montvale, NJ: Medical Economics Company, Inc; 1999:1548.
    1. Cruickshank JM, McAinsh J. Atenolol and ischemic heart disease: an overview. Curr Med Res Opin. 1991;12:485–496. - PubMed
    1. Wadworth AN, Murdoch D, Brogden RN. Atenolol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 1991;42:468–510. doi: 10.2165/00003495-199142060-00009. - DOI - PubMed

LinkOut - more resources